CONTEXT

1
Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs for 2 the treatment of hyperprolactinemia may be associated with clinically significant valvular heart 3 disease; and whether current regulatory authority guidelines for echocardiographic screening are 4 clinically appropriate.
5
OBJECTIVE
6
To provide follow-up echocardiographic data on a previously described cohort of patients treated 7 with DA for lactotrope pituitary tumors; and to explore possible associations between structural 8 and functional valve abnormalities with the cumulative dose of drug used.
9
DESIGN
10
Follow-up echocardiographic data were collected from a proportion of our previously reported 11 cohort of patients; all had received continuous DA therapy for at least 2 years in the intervening 12 period. Studies were performed according to British Society of Echocardiography minimum 13 standards for adult transthoracic echocardiography. Generalised estimating equations with 14 backward selection were used to determine odds ratios of valvular heart abnormalities according 15 to tertiles of cumulative cabergoline dose, using the lowest tertile as the reference group.
16
SETTING
17
Thirteen centers of secondary/tertiary endocrine care across the United Kingdom.
18
RESULTS
19
There were 192 patients (81 males; median age, 51 years; interquartile range [IQR] , 42-62). 
25
CONCLUSION
26
This large UK follow-up study does not support a clinically significant association between the 27 use of DA for the treatment of hyperprolactinemia and cardiac valvulopathy. or severe by integrating multiple indices of severity 4, 19 . As in our previous study, potentially 79 clinically significant valvular disease (morphological or functional) was considered to be 80 moderate or above.
28
INTRODUCTION
Statistical Analysis
83
TTE parameters were described using medians and IQRs. 
RESULTS
97
Of the 192 patients, there were 88 (46%) with a microadenoma, 93 (48) had a macroadenoma 98 and in the remainder it was not specified by the referring physician. Median (IQR) cumulative 99 cabergoline doses at the time of the first and second TTEs were 97mg (20-377) and 232mg (91-100 551) respectively. Median (IQR) weekly cabergoline dose was 0.5mg (0.5-1.0). Median (IQR) 101 duration of uninterrupted cabergoline therapy between the two studies was 34 months (24-42).
102
There were 11 echocardiographic abnormalities of moderate severity at the time of the first TTE.
103
Of these, 6 had become mild by the time of the second study, 4 were unchanged and in 1 patient risk factors for heart disease and no differences were observed when patients with micro-and 114 macro-adenomas were analysed separately.
DISCUSSION
In this study we have performed detailed, follow-up TTE in a large cohort of patients with 118 hyperprolactinemia who, in addition to being exposed to DA therapy before the first 119 examination, received uninterrupted treatment for at least two years before the second.
120
Compared to our previous report, this cohort of patients contains a greater proportion of men and 121 patients classified as having a macroadenoma. This is likely to reflect the higher background 122 remission rate in women and of microadenomas such that some of these originally reported 123 patients will have discontinued DA at some stage in the intervening period and not have been To our knowledge, this is the largest follow-up echocardiographic study of hyperprolactinemic 169 patients treated with DA. Although the size is an obvious strength, as in our previous study, an 170 obvious weakness is the lack of a true control group, with the lowest tertile of DA exposure 171 serving as our 'surrogate control'. In an earlier follow-up study, statistically significant increases 172 in aortic valve calcification were observed with DA therapy, although these changes did not 173 translate into any alterations in valve function 7, 23 . Moreover, while grading the extent of valve echocardiography is subjective and has high inter-observer variability 25 . This could simply be that cardiac valvulopathy develops over a prolonged time period and that clinically significant 177 functional changes (defined in most studies as moderate severity or above) cannot be detected Reassuring group data can sometimes conceal clinically important effects in small numbers of 185 patients. It is for this reason that we present the details of the 9 moderate or above 186 echocardiographic abnormalities in 7 patients seen at the second TTE; these cases illustrate some 187 of the challenges of interpreting echocardiographic findings in this context. The median age of 188 the 7 patients was 74; all except one patient was older than the median age of the overall cohort.
189
Although this may suggest the observed abnormalities were age-related, this group of patients 190 were also heavily exposed to DA; all except one patient had received a cumulative cabergoline 
